SCHEMBL5373591

SCHEMBL5373591

Cc1ccc(S(=O)(=O)Nc2ccc(OCCc3csc(-c4ccc(OC(F)(F)F)cc4)n3)cc2)cc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
RORC P51449 1/20 0.47
SHMT2 P34897 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
TP53 P04637 4/20 0.43
RXRA P19793 1/20 0.43
MAPT P10636 3/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
GSK3B P49841 3/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376953 0.92 TP53 (0.50) POLBSMN1; SMN2ADRB2ADRB1ADRB3
SCHEMBL4904185 0.86 LMNA (0.54) POLBSHMT2SMN1; SMN2TP53MAPT
SCHEMBL4902626 0.85 LMNA (0.49) POLBSHMT2SMN1; SMN2TP53MAPT
SCHEMBL5320408 0.81 POLB (0.69) POLBRORCSMN1; SMN2TP53MAPT
SCHEMBL4908934 0.81 LMNA (0.57) POLBSHMT2SMN1; SMN2TP53MAPT
SCHEMBL5372119 0.80 POLB (0.62) POLBSMN1; SMN2MEN1PKMKMT2A
SCHEMBL4904129 0.79 LMNA (0.51) POLBSHMT2SMN1; SMN2TP53MAPT
SCHEMBL5378686 0.77 POLB (0.61) POLBRORCSMN1; SMN2TP53RXRA
SCHEMBL4899842 0.77 MAPT (0.65) POLBSMN1; SMN2TP53MAPTLMNA
SCHEMBL4895694 0.76 LMNA (0.65) POLBSMN1; SMN2TP53MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885RORC 87/4885SHMT2 423/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885RORC 100/4885SHMT2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.